Instil Bio to Present at Upcoming Investor Conferences in September
Instil Bio, Inc. (NASDAQ: TIL) announced its participation in two investor conferences this September. The first is the Morgan Stanley 19th Annual Global Healthcare Conference on September 9 at 2:00 p.m. ET, featuring a fireside chat. Following that, Instil will present at Baird’s 2021 Virtual Global Healthcare Conference on September 14 at 5:30 p.m. ET. Live webcasts of these events will be available on the company’s website, with archived recordings accessible after the events.
- None.
- None.
DALLAS, Sept. 02, 2021 (GLOBE NEWSWIRE) -- Instil Bio, Inc. (“Instil”) (NASDAQ: TIL), a clinical-stage biopharmaceutical company focused on developing tumor infiltrating lymphocyte, or TIL, therapies for the treatment of patients with cancer, today announced that company management will participate in two upcoming investor conferences in September:
Morgan Stanley 19th Annual Global Healthcare Conference
Fireside Chat: Thursday, September 9 at 2:00 p.m. ET
Baird’s 2021 Virtual Global Healthcare Conference
Company Presentation: Tuesday, September 14 at 5:30 p.m. ET
A live webcast, if recorded, of each presentation can be accessed under “News & Events” in the Investors section of the Company’s website at www.instilbio.com. The archived webcast will be available on the Company’s website shortly after the event.
About Instil Bio
Instil Bio, Inc. (Nasdaq: TIL) is a clinical-stage biopharmaceutical company focused on developing tumor infiltrating lymphocyte, or TIL, therapies for the treatment of patients with cancer. The Company has assembled an accomplished management team with a successful track record in the development, manufacture, and commercialization of cell therapies. Using the Company’s proprietary, optimized, and scalable manufacturing processes at its in-house manufacturing facilities, Instil is advancing its lead TIL product candidate, ITIL-168, for the treatment of advanced melanoma and other solid tumors as well as ITIL-306, a next-generation, genetically engineered TIL therapy for multiple solid tumors. For more information visit www.instilbio.com and LinkedIn.
Contacts:
Brendan Payne
Stern Investor Relations
1-212-362-1200
brendan.payne@sternir.com
Media Contact:
1-833-446-7845 Ext. 1009
mediarelations@instilbio.com
FAQ
What are the dates of the upcoming investor conferences for TIL?
What time will TIL present at the Morgan Stanley conference?
Where can I watch the presentations of TIL's investor conferences?
What is the focus of Instil Bio's research and development?
What are the lead product candidates of TIL?
